Genitourinary Radiology: Page 5

Health disparities persist despite decline in cancer mortality rates
By Amerigo Allegretto
While cancer mortality rates declined in the U.S. between 2000 and 2020, racial and ethnic disparities persisted for many cancers.
January 15, 2024
Patient African American Woman 400
MRI helps clinicians assess neural involvement in endometriosis
By Kate Madden Yee
MRI could help clinicians assess neural involvement in endometriosis and help prevent irreversible nerve damage and chronic sensorimotor neuropathy.
January 4, 2024
Spectrum of imaging features of nerves involved in endometriosis in three women. (A) Coronal T1W contrast-enhanced MR image in a 44-year-old woman shows a thickened left sciatic nerve with increased enhancement (solid arrows) and a fibrotic mass (*). The right-side sciatic nerve is normal in appearance (dashed arrows). (B-D) Axial T1W image (without contrast enhancement) with fat saturation (B) in a 43-year-old woman shows a cystic endometriotic lesion with signal hyperintensity (arrow in B). The adjacent left iliacus muscle is asymmetrically thickened due to involvement by endometriosis (* in B). Axial T2-weighted MR image (C) at the same level as B shows T2 shading in the cystic lesion (arrow in C) and a fibrotic mass replacing the iliacus muscle (* in C). Sagittal T2-weighted MR image (D) shows the sacral nerve roots (dashed arrows in D) encased by a fibrotic endometriotic mass (* in D). (E) Axial T2-weighted MR image in a 37-year-old woman shows atrophy of the left iliopsoas (solid oval) and sartorius muscles (dashed oval), both innervated by the femoral nerve. Images and caption courtesy of the RSNA.
MRI comparable to Ga-68 PSMA PET/CT for prostate cancer diagnosis
By Kate Madden Yee
MRI performs comparably to gallium-68 (Ga-68) PSMA PET/CT for prostate cancer diagnosis and treatment tracking, according to research delivered at the recent RSNA meeting.
December 20, 2023
Prostate 3 D 400
AI predicts responses in patients with prostate cancer
By Will Morton
An AI model based on F-18 DCFPyL PSMA-PET/CT images shows promise for predicting treatment response in patients with metastatic castration-resistant prostate cancer.
December 12, 2023
Prostate Cancer
PET tracer shows promise in prostate cancer patients
By Will Morton
Gallium-68 RM2-PET/MRI is better than MRI alone for detecting relapse in prostate cancer patients, according to research presented at RSNA 2023.
November 26, 2023
An image showing potentially different sites of PET radiotracer uptake by prostate cancer tumors between U.S. approved Ga-68 PSMA-PET and experimental Ga-68 RM2. Image courtesy of Heying Duan, MD, Stanford University.
Elastography predicts treatment response in colorectal cancer patients
By Amerigo Allegretto
Elastography could help with treatment strategies for colorectal cancer patients, a study presented November 26 at the RSNA annual meeting found.
November 26, 2023
Jae Seok Bae, MD, from Seoul National University Hospital presented research at RSNA showing the efficacy of shear-wave elastography in predicting chemotherapy response in colorectal patients.
Features found on MRI may predict liver cancer recurrence after surgery
By Kate Madden Yee
An algorithm based on MRI features could help clinicians predict liver cancer recurrence after patients have undergone liver resection, researchers have found.
November 8, 2023
Preoperative axial extracellular contrast agent-enhanced (A-E) MRI and (F-H) follow-up CT images in a 71-year-old male patient with chronic hepatitis B and a serum neutrophil count of 4.2 × 109/L. A 5.6-cm mass with a 1.9-cm satellite nodule was detected in segments V and VIII. (A) The mass (asterisks, A-E) shows mild-to-moderate hyperintensity on T2-weighted images, (B) hypointensity on T1-weighted noncontrast-enhanced images, (C) less than 50% hyperenhancement on late arterial phase images, (D) nonperipheral washout and incomplete enhancing capsule on portal venous phase images, and (E) marked diffusion restriction on diffusion-weighted images (b = 800 sec/mm2). The mass was confirmed at histopathologic analysis as moderately differentiated hepatocellular carcinoma with microvascular invasion. With an advanced-stage recurrence after resection score of 19.8 points (4.2 + 5.6 + 10), this patient was assigned to the high-risk group (≥15 points) for advanced-stage recurrence. At follow-up, (F) noncontrast-enhanced, (G) arterial phase, and (H) portal venous phase CT images acquired at day 70 after surgery show multifocal intrahepatic recurrence and tumor thrombus in the left portal vein (black arrow, H). Images and caption courtesy of the RSNA.
PET/CT-based model predicts prostate cancer in the 'PSA grey zone'
By Will Morton
Combining PET/CT with traditional clinical risk factors can detect prostate cancer in cases considered borderline based on prostate-specific antigen (PSA) levels -- in other words, cases in the "PSA grey zone," according to a group in Hunan, China.
September 10, 2023
2023 09 08 15 10 4007 2023 09 08 Prostate Cancer 20230908154926
COVID-19 pandemic led to apparent decreases in cancer incidence
By Amerigo Allegretto
The COVID-19 pandemic led to apparent decreases in cancer incidence for several cancer types, suggest Canadian findings published September 5 in JAMA Network Open.
September 5, 2023
2023 09 05 21 24 9441 Covid 19 Second Wave 400
PET/CT and PET/MRI appear equivalent for diagnosing prostate cancer
By Will Morton
PET/CT and PET/MRI have gone head-to-head for detecting prostate cancer relapse in a review that included 37 clinical studies and 8,709 patients -- with PET/MRI taking a slight lead, according to a team in China.
August 31, 2023
2019 04 17 20 48 2514 Prostate 3 D 400
CLS Americas inks partnership with Focalyx
By AuntMinnie.com staff writers
Clinical Laserthermia Systems (CLS) Americas has inked a comarketing agreement with Focalyx for image-guided focal laser ablation of prostate tumors.
August 27, 2023
2019 04 17 20 48 2514 Prostate 3 D 400
Are PSMA-PET tracers equal in detecting prostate cancer?
By Will Morton
Researchers in China have provided some clarity for clinicians over which prostate-specific membrane antigen (PSMA) radiotracer may be best for PET/CT prostate cancer imaging, according to a study published August 21 in Cancer Imaging.
August 27, 2023
2019 04 17 20 48 2514 Prostate 3 D 400
Previous Page
Page 5 of 93
Next Page